MBP146-78

• CAT Number: I013665
• CAS Number: 188343-77-3
• Molecular Formula: C₂₁H₂₂FN₃
• Molecular Weight: 335.42
• Purity: ≥95%
• Target: Parasite
• Solubility: 10 mM in DMSO
• IUPAC Name: 4-[2-(4-fluorophenyl)-5-(1-methylpiperidin-4-yl)-1H-pyrrol-3-yl]pyridine
• InChI: InChI=1S/C21H22FN3/c1-25-12-8-16(9-13-25)20-14-19(15-6-10-23-11-7-15)21(24-20)17-2-4-18(22)5-3-17/h2-7,10-11,14,16,24H,8-9,12-13H2,1H3
• InChIKey: RBWNFHXBUDPAIO-UHFFFAOYSA-N
• SMILES: CN1CCC(CC1)C2=CC(=C(N2)C3=CC=C(C=C3)F)C4=CC=NC=C4

MBP146-78（Cat No.:I013665）is an investigational compound under evaluation for its potential therapeutic applications in treating infectious and inflammatory diseases. It exhibits a unique mechanism of action targeting specific cellular pathways to modulate immune responses or inhibit pathogenic activity. Designed with high specificity and bioavailability, MBP146-78 holds promise in addressing conditions resistant to conventional treatments. Its development focuses on achieving optimal efficacy while minimizing side effects, making it a valuable candidate for future clinical applications. Current studies aim to establish its safety profile and therapeutic potential across various disease models.

Reference

[1]. Nare B, et al. Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy. Antimicrob Agents Chemother. 2002 Feb;46(2):300-7.